In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate
Some cookies are essential and the website may not work correctly without them. These cookies can only be removed by changing your browser preferences.
Other cookies
We use tracking cookies and other non-essential cookies to help improve our services.
We place cookies on your device to give you the best experience of this website. If you don't change your cookie settings, we'll assume you're happy with this.